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Abstract
Plasmodium vivax invasion of human erythrocytes depends on the Duffy Binding Protein
(PvDBP) which interacts with the Duffy antigen. PvDBP copy number has been recently
shown to vary between P. vivax isolates in Sub-Saharan Africa. However, the extent of
PvDBP copy number variation, the type of PvDBP multiplications, as well as its significance
across broad samples are still unclear. We determined the prevalence and type of PvDBP
duplications, as well as PvDBP copy number variation among 178 Ethiopian P. vivax iso-
lates using a PCR-based diagnostic method, a novel quantitative real-time PCR assay and
whole genome sequencing. For the 145 symptomatic samples, PvDBP duplications were
detected in 95 isolates, of which 81 had the Cambodian and 14 Malagasy-type PvDBP dupli-
cations. PvDBP varied from 1 to >4 copies. Isolates with multiple PvDBP copies were found
to be higher in symptomatic than asymptomatic infections. For the 33 asymptomatic sam-
ples, PvDBP was detected with two copies in two of the isolates, and both were the Cambo-
dian-type PvDBP duplication. PvDBP copy number in Duffy-negative heterozygotes was
not significantly different from that in Duffy-positives, providing no support for the hypothesis
that increased copy number is a specific association with Duffy-negativity, although the
number of Duffy-negatives was small and further sampling is required to test this association
thoroughly.
Author summary
Plasmodium vivax invasion of human erythrocytes relies on interaction between the
Duffy antigen and P. vivax Duffy Binding Protein (PvDBP). Whole genome sequences
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from P. vivax field isolates in Madagascar identified a duplication of the PvDBP gene and
PvDBP duplication has also been detected in non-African P. vivax-endemic countries.
Two types of PvDBP duplications have been reported, termed Cambodian and Malagasy-
type duplications. Our study used a combination of PCR-based diagnostic method, a
novel quantitative real-time PCR assay, and whole genome sequencing to determine the
prevalence and type of PvDBP duplications, as well as PvDBP copy number on a broad
number of P. vivax samples in Ethiopia. We found that over 65% of P. vivax isolated from
the symptomatic infections were detected with PvDBP duplications and PvDBP varied
from 1 to>4 copies. The majority of PvDBP duplications belongs to the Cambodian-type
while the Malagasy-type duplications was also detected. For the asymptomatic infections,
despite a small sample size, the majority of P. vivax were detected with a single-copy based
on both PCR and qPCR assays. There was no significant difference in PvDBP copy num-
ber between Duffy-null heterozygote and Duffy-positive homozygote/heterozygote. Fur-
ther investigation is needed with expanded Duffy-null homozygotes to examine the
functional significance of PvDBP expansion.
Introduction
Plasmodium vivax and P. falciparum are the two major parasite species that cause clinical
malaria worldwide. While P. falciparum causes most malaria mortality, P. vivax can also cause
severe disease and, more rarely death [1,2]. P. vivax is prominent in India, Southeast Asia, and
South America. By contrast, vivax malaria is rare in sub-Saharan Africa, with significant rates
of infection only found in a few countries [3]. The rarity of this infection is tightly associated
with high prevalence of Duffy negativity in West and Central Africa [4]. This association rep-
resents a classic example of innate resistance to a pathogen resulting from the absence of a
receptor for the pathogen [5]. A point mutation in the GATA-1 transcription factor binding
site of the Duffy antigen/receptor for chemokines (DARC) gene promoter eliminates Duffy
antigen (Fy) expression on the RBC surface required for P. vivax invasion [6]. This phenome-
non is thought to account for the lack of P. vivax malaria in sub-Saharan Africa.
In Ethiopia, P. vivax and P. falciparum account for approximately 40% and 60% of the
malaria cases, respectively [7,8]. The proportion of Duffy negatives in Ethiopia is about 35%
[9,10], considerably lower than that documented in West and Central Africa (>97%) [4].
About 20% of hospital patients presented with malaria symptoms are Duffy-negatives [10–11].
While Duffy negativity was previously thought to be associated with complete resistance to P.
vivax, P. vivax infection in Duffy-negative individuals was confirmed unequivocally in Mada-
gascar [12], and has also been observed in multiple other parts of Africa as well as other parts
of the world [13–18].
Plasmodium vivax invasion of human erythrocytes relies on interaction between the Duffy
antigen and P. vivax Duffy Binding Protein (PvDBP) [19–20], though other reticulocyte
ligand-receptor have also been recently identified [21]. Our recent study has shown that muta-
tions in PvDBP do not explain the ability of P. vivax parasites to infect Duffy-negative individ-
uals [22], but there could be other molecular mechanisms at play. Whole genome sequences
from P. vivax field isolates in Madagascar identified a duplication of the PvDBP gene [23] and
PvDBP duplication has also been detected in non-African P. vivax-endemic countries [24, 25].
In Ethiopia, PvDBP expansion has been reported with a 79% prevalence in a recent analysis of
24 P. vivax genomes [26]. However, sample size was relatively limited and the extent of copy
number variation among broad samples is still unclear. The high prevalence of PvDBP
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duplications raises the possibility that it is linked to the ability of P. vivax to infect Duffy-nega-
tive individuals.
Two types of PvDBP duplications have been reported, termed Cambodian and Malagasy-
type duplications based on the samples in which they were first described [23–24]. Both create
a complete duplication of the PvDBP gene, but they differ in the sequence and length of the 3’-
boundary of the linker region between the tandem copies of PvDBP [24]. In this study, we
used whole genome sequencing and PCR-based diagnostic methods to determine the preva-
lence of both the Madagascar- and Cambodia-type PvDBP duplications in southwestern Ethio-
pia where a high incidence of P. vivax infections and a modest proportion of Duffy-null
individuals co-occur. We compared PvDBP copy number between Duffy-null heterozygotes
(FyA/BES or FyB/BES) and homozygotes (FyBES/BES), between symptomatic and asymptomatic
infections, and explored the correlation of gene copy number with parasitemia, age, gender,
ethnicity, and malaria symptoms in order to shed light on the epidemiological significance of
PvDBP duplications.
Materials and methods
Ethics statement
Scientific and ethical clearance was given by the institutional scientific and ethical review
boards of the Jimma University, Ethiopia, and University of North Carolina at Charlotte, USA.
Written informed consent/assent for study participation was obtained from all consenting
heads of households, parents/guardians (for minors under age of 18), and each individual who
was willing to participate in the study. All experimental protocols were reviewed and approved
by the institutional review board (IRB) of the University of North Carolina at Charlotte, USA
and performed in accordance with the IRB guidelines and regulations.
Sample collection
A total of 178 P. vivax samples were included in this study. They were isolated from 145 symp-
tomatic patients and 33 asymptomatic volunteers in Jimma, Ethiopia that had previously been
confirmed by microscopy and PCR to be infected with P. vivax [9,10]. Symptomatic samples
were obtained from patients who visited the health centers/hospitals in the Jimma town and
presented with malaria signs/symptoms including axillary temperature�37˚C, vomiting, diar-
rhea, nausea, abdominal pain, chills, fatigue, muscle pain, headache, malaise or loss of appetite
(S1 Table). The asymptomatic samples were obtained from the community in the same area
and had no fever or other malaria symptoms at the time of collection. Thick and thin blood
smears were prepared for each subject to screen for P. vivax by microscopy. Parasites were
counted against 200 leukocytes and a slide was considered negative when no parasites were
observed after counting over 100 microscopic fields. All slides were read in duplicate by two
microscopists at the time of sample collection. The density of parasitemia was expressed as the
number of asexual P. vivax per microliter of blood, assuming a leukocyte count of 8000 per
microliter. Three to four blood spots, each equivalent to ~50μl of blood, were blotted on What-
man 3MM filter paper from each participating individual. Parasite DNA was extracted from
dried blood spots by the Saponin/Chelex method [27] and genomic DNA was eluted in a total
volume of 200 μl TE buffer. Eluted DNA was confirmed with P. vivax by nested and quantita-
tive PCR using the 18S rRNA P. vivax-specific primers [10], prior to PCR diagnosis of PvDBP
duplications and quantification of copy number.
For a subset of 20 symptomatic samples that were confirmed with P. vivax, 6ml whole
blood was collected from the patients. We used the Lymphoprep/Plasmodipur-based protocol
to deplete white cells and enrich red cells before DNA extraction [28]. DNA was extracted
Plasmodium vivax DBP expansion and epidemiological significance
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from the enriched RBCs using the ZymoBead Genomic DNA kit (Zymo Research) following
the manufacturer’s procedures. Whole genome sequences were obtained for these samples on
a HiSeq Illumina Sequencing Platform at the Wellcome Trust Sanger Institute (ENA accession
number of each sample in Table 1). The generated sequence reads were mapped individually
to the P. vivax PVP01 reference genome [29] using bwa version 0.5.9-r16 with default parame-
ters [30]. The resulting assembly bam files were reviewed in the region containing PvDBP
(chromosome 6: 976329–980090) using the Artemis genome viewer [31]. Using a “non-proper
pair” read filter in Artemis, mate pairs that were oriented tail-to-tail indicated PvDBP duplica-
tions [24].
Quantification of Plasmodium vivax DNA
The amount of P. vivax DNA in each sample was estimated using the SYBR Green quantitative
PCR detection method using primers that targeted the 18S rRNA genes of P. vivax [10].
Amplification was conducted in a 20 μl reaction mixture containing 1 μL of genomic DNA,
10 μl 2×SYBR Green qPCR Master Mix (Thermo Scientific), and 0.5 uM primer. The reactions
were performed in CFX96 TouchTM Real-Time PCR Detection System (BIORAD), with an
initial denaturation at 95˚C for 3 min, followed by 45 cycles at 94˚C for 30 sec, 55˚C for 30 sec,
and 68˚C for 1 min with a final 95˚C for 10 sec. This was followed by a melting curve step of
temperature ranging from 65˚C to 95˚C with 0.5˚C increments to determine the melting tem-
perature of the amplified product. Each assay included positive controls of P. vivax Pakchong
(MRA-342G) and Nicaragua (MRA-340G) isolates, in addition to negative controls including
uninfected samples and water. A standard curve was produced from a ten-fold dilution series
of the control plasmids to determine the amplification efficiency. Melting curve analyses were
performed for each amplified sample to confirm specific amplifications of the target sequence.
A cut-off threshold of 0.02 fluorescence units that robustly represented the threshold cycle at
the log-linear phase of the amplification and above the background noise was set to determine
Ct value for each assay. The mean Ct value was calculated from three independent assays of
each sample. Samples yielding Ct values higher than 40 (as indicated in the negative controls)
were considered negative for Plasmodium species. The amount of parasite DNA in a sample
was quantified using the follow equation: Parasite DNA (/uL) = [2 E×(40-Ctsample)/10]; where Ct
for the threshold cycle of the sample, and E for amplification efficiency; assuming 10,000 18S
rRNA copies/mL (i.e., 10 copies/uL) in each Plasmodium genome [32].
PCR diagnosis of PvDBP duplications
Two sets of primers were used to examine the prevalence and type of PvDBP duplications fol-
lowing published protocols [23, 24]. The first set of primers includes AF+AR, BF+BR, and BF
+AR [23]. Primers BF+AR amplify a 612-bp product that contains the junction between the
PvDBP copies in isolates with the Malagasy-type duplications. The second set of primers
includes AF2+AR2, BF+BR, and BF+AR2 [24]. Primers BF+AR2 amplify a 736-bp product
that contains the junction between the PvDBP copies in isolates with the Cambodia-type dupli-
cation. This primer pair, in theory, should also amplify a 1584-bp product should there be Mal-
agasy-type duplications. Without duplications, BF+AR and BF+AR2 primers are opposite-
facing in the samples and thus do not amplify a product [24].
Estimation of PvDBP copy number by qRT-PCR
PvDBP copy number was measured with a SYBR Green qPCR detection method using primers
(forward: 5’-AGGTGGCTTTTGAGAATGAA-3’; reverse: 5’-GAATCTCCTGGAACCTTCT
C-3’) designed between region II to III of PvDBP (PVX_110810). Plasmodium vivax aldolase,
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which is known to be a single-copy gene, was used as an internal reference to calculate gene
copy number [33]. Two Cambodian isolates, Pv0430 and Pv0431, which were confirmed previ-
ously by whole genome sequencing to contain a single and two PvDBP copies [24], respec-
tively, were included in each run as positive controls. Water was used as a no DNA control.
Table 1. Information of whole genome sequences of 20 Plasmodium vivax isolates from Ethiopia. The European Nucleotide Archive (ENA) accession number for all
files (ERP012186).
Whole genome sequence PCR diagnosis qPCR
Blood
sample
ENA
accession
number
All reads P. vivax
reads (%)
Average
genome
coverage
PvDBP
coverage
PvDBP
copy
Mate/Cvg
support §
(Yes/No)
Duplication type
[23,24]
(Cambodian/
Malagasy)
Genome
covered
15X (%)
Malagasy
duplication
BF+AR
(Yes/No)�
Cambodia
duplication
BF+AR2
(Yes/No)�
GCN
BBH
(1)-125
ERS849384 16104099 14765167
(92%)
83.11 352.9 4.25 Yes Cambodian 99.6 No Yes 4.30
BBH
(1)-132
ERS2593850 295443478 269499723
(91%)
582.99 548.8 0.94 No Single copy 98.5 No No 1.14
BBH
(1)-137
ERS2593862 15428892 12612040
(82%)
41.09 99.14 2.41 Yes Cambodian 96.1 No Yes 3.58
BBH
(1)-153
ERS2593851 19596872 17206221
(88%)
57.34 149.17 2.6 Yes Cambodian 97.6 No Yes 3.86
BBH
(1)-162
ERS2593852 322082372 32342978
(10%)
72.36 102.41 1.42 No Single copy 98.5 No No 0.93
HT(1)-
144
ERS2593853 16508858 8025807
(49%)
28.52 30.73 1.08 No Single copy 95.9 No No 1.18
HT(1)-
147
ERS2593863 118998744 97833898
(82%)
234.14 761.45 3.25 Yes Cambodian 98 No Yes 3.71
HT(2)-
112
ERS2593864 44338048 23619451
(53%)
73.45 83.3 1.13 No Single copy 97.6 No No 1.20
JHC
(1)-208
ERS2593865 381752146 294998614
(77%)
112.34 254.12 2.26 Yes Cambodian 98.7 No Yes 2.70
JHC
(2)-100
ERS2593855 17622060 15958894
(91%)
56.23 166.06 2.95 Yes Cambodian 97.3 No Yes 3.24
MKH
(1)-72
ERS2593857 17668719 14101177
(80%)
57.11 53.41 0.94 No Single copy 97.2 No No 1.28
MKH
(2)-71
ERS2593866 217327926 208538370
(96%)
715.07 1746.88 2.44 Yes Malagasy 98.5 Yes No 3.69
SGH
(1)-355
ERS2593858 18782232 17776334
(95%)
75.92 104.84 1.38 No Single copy 97 No No 1.54
SGH
(1)-357
ERS2593859 82415713 51869956
(63%)
106.63 469.81 4.41 Yes Malagasy 98 Yes No 5.14
SGH
(1)-331
ERS849385 17931182 16408183
(92%)
90.97 79.85 0.88 No Single copy 99.7 No No 1.00
SGH
(1)-337
ERS2593867 16492008 7883420
(48%)
29.05 79.25 2.73 Yes Cambodian 95 No Yes 3.44
SGH
(1)-358
ERS2593868 13579936 7433474
(55%)
27.75 80.08 2.89 Yes Cambodian 95.8 No Yes 3.86
SGH
(1)-359
ERS2593869 24113148 15808023
(66%)
46.36 118.61 2.56 Yes Cambodian 97.9 No Yes 3.51
SGH
(2)-103
ERS2593861 33312612 29984852
(90%)
123.54 272.61 2.21 Yes Cambodian 97.8 No Yes 4.40
SGH
(2)-108
ERS2593871 6209652 4333558
(70%)
16.45 27.06 1.64 Yes Cambodian 64.2 No Yes 2.82
§ ‘Yes’ indicates PvDBP duplication; ‘No’ indicates a single copy.
� ‘Yes’ indicates an amplification product was observed in the PCR; ‘No’ indicates no amplification was observed.
https://doi.org/10.1371/journal.pntd.0007222.t001
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Amplification was conducted in a 20μL reaction mixture containing 1μL of genomic DNA
(all samples was standardized to ~50 genomes/μL in each reaction based on 18S qPCR assay;
S2 Table), 10μL 2×SYBR Green qPCR Master Mix (Thermo Scientific, USA), and 0.5μM of
each primer. Reaction was performed in CFX96 TouchTM Real-Time PCR System (Bio-Rad)
with an initial denaturation at 95˚C for 3 min, followed by 45 cycles at 94˚C for 30 sec, 55˚C
for 30 sec, and 68˚C for 1 min with a final 95˚C for 10 sec [22]. This was followed by a melting
curve step of temperature ranging from 65˚C to 95˚C with 0.5˚C increments to determine the
melting temperature of the amplified product. Each assay included an internal reference P.
vivax aldolase as well as the negative controls (uninfected samples and water). Melting curve
analyses were performed for each amplified sample to confirm specific amplifications of the tar-
get sequence. A cut-off threshold of 0.02 fluorescence units that robustly represented the thresh-
old cycle at the log-linear phase of the amplification and above the background noise was set to
determine Ct value for each assay. The amplification of the P. vivax aldolase and PvDBP gene
fragments was optimized to obtain similar amplification efficiency. The mean Ct value and stan-
dard error was calculated from three independent assays of each sample (S3 Table). PvDBP copy
number (N) was calculated with the equation previously used for Pvmdr1 copy number estima-
tion [33] as follow: N = 2ΔΔCt±SD, where ΔΔCt = (Ctpvaldo- Ctpvdbp)-(Ct pvaldo cal-Ct pvdbp cal). The
Ctpvaldo and Ctpvdbp are threshold cycle values for the P. vivax aldolase and PvDBP genes respec-
tively, whereas Ctcal is an average difference between Ctpvaldo and Ctpvdbp obtained for the posi-
tive control containing a single copy of the P. vivax aldolase and PvDBP gene fragments (i.e., the
Cambodian isolate Pv0430 in this case). The SD value is a standard deviation calculated as fol-
low: SD =
p
(S2pvdbp+S
2
pvaldo+S
2
cal) where Spvdbp and Spvaldo are the standard deviations from the
average Ct calculated for three replicates in the P. vivax aldolase and PvDBP gene amplifications.
Scal is an average standard deviation of the ΔCt values for the calibrator. The PvDBP copy num-
ber of each sample was assessed twice for validation.
Duffy blood group genotyping
For all P. vivax positive samples, a 1,100-bp fragment of the human Duffy blood group antigen
gene that encompasses the GATA1 transcription factor-binding site of the gene promoter was
amplified using published primers [12]. PCR reaction contained 20μl DreamTaq PCR Master-
mix, 1μl DNA template, and 0.5μl each primer. PCR conditions were: 94˚C for 2-min, followed
by 35 cycles of 94˚C for 20s,58˚C for 30s, and 68˚C for 60s, followed by a 4-min extension.
PCR products were sequenced and the chromatograms were visually inspected to determine
the Fy genotypes (see Duffy blood group nomenclature in [34]).
Correlation analyses
A one-tailed t-test was used to test for the significance of differences in PvDBP copy number
between symptomatic and asymptomatic P. vivax infections, as well as among Duffy geno-
types. In addition, we calculated Pearson’s correlation coefficient (r2) in R for the associations
of PvDBP copy number with parasitemia and age among the clinical samples. Samples were
also stratified by gender and ethnicity to test if there was a significant difference in PvDBP
copy number. Malaria symptoms including fever, chills, malaise, fatigue, muscle/joint pain,
headache, nausea, vomit, diarrhea, abdomen pain, loss of appetite, and respiratory difficulty
(dependent variables) were recorded as presence or absence for each of the patients. Principle
component analyses were performed to show the variation of all variables among the samples
with different PvDBP copy number using the logistic PCA function in R. A 3-dimensonal PCA
plot was constructed with the plot3d function from the rgl package.
Plasmodium vivax DBP expansion and epidemiological significance
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Results
PvDBP duplications are common in Ethiopian P. vivax infections
To establish whether Cambodian or Malagasy-type PvDBP duplications were present in the
sample population, whole genome sequences were obtained for a subset of 20 Ethiopian P.
vivax samples using Illumina sequencing (Table 1). For these 20 samples, 13 to 381 million 150
bp pair-end reads were generated and 10–96% of these reads was mapped to the P. vivax refer-
ence genome PVP01. The average P. vivax genome coverage was 16–715× with over 95% of
the genome covered by at least 15 reads in the majority of the samples. The average PvDBP
coverage was 27–1746×, of which the sequence coverage of the PvDBP region was clearly
higher than the flanking regions in some samples (S1 Fig). We further confirmed and identi-
fied the type of PvDBP duplications by mapping the paired-end reads in a tail-to-tail orienta-
tion, respectively, on the Malagasy M15 [23] and Cambodian PV0431 [24] reference genomes.
Based on whole genome sequences of the duplication break points, two out of the 20 P. vivax
samples contained the Malagasy-type and 11 contained the Cambodian-type duplications. The
remaining had a single copy PvDBP (Table 1).
To test more extensively for PvDBP duplications, we used recently published diagnostic
PCR primers [24]. These primers had previously been used to genotype 20 Ethiopian P. vivax
symptomatic samples [24]. We genotyped an additional 158 (125 symptomatic and 33 asymp-
tomatic) P. vivax samples, bringing the total tested samples to 178 across this and the previous
study. All samples produced bands of the expected size of 650-700bp with the control primers
AF/AR, BF/BR, and AF2/AR2 (Fig 1), indicating the presence of PvDBP in all isolates. Among
them, 14 (9.7%) showed a fragment of ~600bp with the Malagasy duplication primers BF/AR
(e.g., sample SGH(1)-357 in Fig 1), 81 (55.9%) showed a fragment of ~800bp with the Cambo-
dian duplication primers BF/AR2 (e.g., BBH(1)-125 in Fig 1), and 50 (34.5%) showed no
amplifications with either pair of primers (e.g., BBH(1)-132 in Fig 1), suggesting either they
only contained a single copy of PvDBP or a duplication not detected by either primer pair. For
Fig 1. Ethiopian P. vivax samples contain both the Malagasy- and Cambodian-type duplications. AF/AR, BF/BR
and AF2/AR2 are control primers where all samples indicated amplifications except the negative control sample.
Sample SGH(1)-357produced a band of ~650bp with BF/AR primers, indicative of a Malagasy PvDBP duplication.
Sample BBH(1)-125produced a band of ~750bp with BF/AR2 primers, indicative of a Cambodian PvDBP duplication.
Sample BBH(1)-132showed no amplification with both BF/AR and BF/AR2 primers, indicative of a single PvDBP
region without any duplications. No bands were observed for DNA-negative control (-) in all amplifications.
https://doi.org/10.1371/journal.pntd.0007222.g001
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the 14 samples that showed amplification with the Malagasy duplication primers BF/AR, two
were amplified with the Cambodian primers BF/AR2 giving a ~1,500bp band.
A quantitative PCR (qPCR) assay reveals higher order copy number
variants in some samples
To test whether additional duplication types not detected by these primer pairs were present,
we developed a qPCR assay that compared the quantity of PvDBP products to that of a known
single copy gene control, P. vivax aldolase. To validate the assay, we compared PvDBP copy
numbers estimated by qPCR with those estimated by PCR diagnostic primers (BF/AR and BF/
AR2) and from whole genome sequencing for the 20 samples that had been whole genome
sequenced (Table 1). There was a significant correlation between these two metrics (Fig 2A),
confirming that the qPCR assay was measuring changes in copy number. For 50 samples that
showed no amplification with primers BF/AR and BF/AR2, indicative of a single copy gene,
qPCR copy number estimates ranged from 0.85–1.77 (a median value of 1.17±0.26; Fig 2B).
Six of these samples had also been whole genome sequenced, and had fold-coverage of PvDBP
ranging from 0.88–1.42, confirming the presence of only a single PvDBP copy (Table 1; Fig
2B). We therefore used qPCR estimates of>1.9 to score samples containing multiple PvDBP
copies.
Among the 145 symptomatic samples, there were 95 samples with PvDBP qPCR copy num-
ber estimates>1.9, and all of these also showed amplifications with BF/AR or BF/AR2 primers,
confirming the presence of more than one PvDBP copy. qPCR estimates for these samples ran-
ged from 1.90–6.91 (Fig 2B), suggesting that some samples might contain higher order amplifi-
cations. We subdivided these samples into two categories: (1) samples with value < 3.5 were
defined as 2–3 PvDBP copies and (2) samples with value�3.5 were defined as�4 PvDBP cop-
ies. By this definition, 71 samples had 2–3 PvDBP copies (48.9%; median value of 2.42 ± 0.49)
and 24 had� 4 PvDBP copies (16.5%; median value of 4.40 ± 0.89; Fig 2B). This is to our
Fig 2. Comparison of PvDBP copy number estimated using different approaches. (A) A scatter plot showing PvDBP copy number estimated by quantitative real-
time polymerase chain reaction (y-axis) and by PvDBP coverage in whole genome sequencing (x-axis) of 20 symptomatic P. vivax samples. Regression coefficient and P-
value were indicated. (B) A dot plot showing PvDBP copy number detected by quantitative real-time PCR of all 145 symptomatic P. vivax samples by three different
copy number categories. The geometric median and standard deviation of the data were indicated.
https://doi.org/10.1371/journal.pntd.0007222.g002
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knowledge the first report of higher order PvDBP copy numbers in a large number of P. vivax
isolates. PvDBP fold coverage estimated from whole genome sequences corroborated the
qPCR results in 16 out of the 20 samples. In four samples, qPCR data estimated >4 PvDBP
copies whereas whole genome sequencing data estimated 2–3 PvDBP copies (S4A Table). For
these four samples, we used the fold-coverage based on the whole genome sequences to score
their copy number category. In total, 95 of 145 symptomatic samples tested (65.5%) had more
than a single copy of PvDBP.
For the 33 asymptomatic samples, two (6.1%) were found with multiple PvDBP copies (Fig
3; S4B Table). The qPCR data was further confirmed with the PCR diagnostic primers BF/AR
and BF/AR2 for all the 33 asymptomatic samples (S4B Table). No amplification was observed
in 31 samples, indicative of the absence of duplication. In two asymptomatic samples, amplifi-
cation was observed with primers BF/AR2, indicative of the Cambodian-type duplication.
Two PvDBP copies were detected by qPCR in these two asymptomatic samples. A ten-fold
higher rate of multi-copy PvDBP infections was observed in symptomatic patients compared
to the asymptomatic volunteers (P< 0.001).
Fig 3. Comparison of PvDBP copy number in symptomatic and asymptomatic P. vivax samples. PvDBP copy number was estimated by qPCR. The
geometric median and stand deviation of the data were shown for each type of infection.
https://doi.org/10.1371/journal.pntd.0007222.g003
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PvDBP copy number expansion correlates with malaria symptoms
Based on DARC gene sequences, 101 of 145 (69.7%) symptomatic P. vivax-infected samples
were Duffy-null heterozygote (FyA/BES or FyB/BES), two (1.4%) were Duffy-null homozygote
(FyBES/BES), 17 (11.7%) were Duffy-positive homozygote (FyA/A or FyB/B) and 25 (17.2%)
were Duffy-positive heterozygote (FyA/B or FyB/X2; S5 Table). Significant differences were
observed in PvDBP copy number between FyA/BES and FyB/BES, FyB/B and FyA/B, FyB/BES
and FyA/B, as well as FyA/BES and FyB/B (Fig 4). While both being Duffy-null heterozygotes,
FyA/BES indicated a significantly higher PvDBP copy number than FyB/BES. Among the
Duffy-positives, heterozygote FyA/B had a significantly higher PvDBP copy number than
homozygote FyB/B. The PvDBP copy number of Duffy-null homozygote FyBES/BES and
Duffy-positive homozygote FyA/A was not compared with other Duffy genotypes because
their sample size was too small to generate significant comparisons (Fig 4). The two asymp-
tomatic samples detected with two PvDBP copies were both Duffy-null heterozygote (FyB/
BES). The remaining samples with a single PvDBP copy comprised both Duffy-null heterozy-
gote and Duffy-positive homozygote and heterozygote (S5 Table).
To investigate whether high PvDBP copy number increases invasion efficiency of the para-
site, the association of parasite densities with PvDBP copy number was examined. No signifi-
cant association was detected between PvDBP copy number and parasite densities in the
symptomatic samples (S2A Fig). We did not examine this correlation in the asymptomatic
samples because of the small sample size. Also, we do not have the parasitemia and demo-
graphic information of the asymptomatic samples. For the symptomatic samples, no signifi-
cant association was detected between PvDBP copy number and age, gender, and ethnicity
(S2B–S2D Fig; S6 Table). The PCA plot based on the first three principle components reflected
99.5% of the total variation from 12 recorded malaria symptoms (Fig 5; S1 Table). No clear
cluster was observed among samples with a single or multiple PvDBP copies, suggesting that
the symptoms of these patients did not relate to PvDBP copy number.
Discussion
PvDBP copy number variation has previously been studied primarily using PCR genotyping.
In this study, we used a quantitative PCR method for estimating copy number, an approach
used in several studies particularly related to human diseases [35]. The qPCR assay outcome
was validated against PCR genotyping and whole genome sequencing methods. We are aware
that difference in the amount of parasite DNA among samples, particularly that between
symptomatic and asymptomatic infections, may influence the quantification of PvDBP copy
number. Therefore, we standardized the amount of parasite DNA in each reaction based on
the results of 18S rRNA quantification prior to PvDBP qPCR assay. Also, for each sample we
used the single-copy P. vivax aldolase gene as internal standard to calibrate and calculate the
PvDBP gene copy number. Given that the results of PvDBP qPCR were consistent with those
by PCR genotyping and whole genome sequencing, we are confident that the estimated
PvDBP copy number was not biased by the amount of parasite DNA in our samples. Quantita-
tive PCR offers a time- and cost-effective approach to analyze a large number of samples, as
unlike whole genome sequencing, it can be performed with relatively little DNA, such as dried
blood samples routinely taken in malaria studies. The genotyping PCR method used in previ-
ous studies of PvDBP copy number has the advantage of providing better detection of PvDBP
duplications in polyclonal infections [23, 24]. However, this method is limited to identifying
only presence or absence of PvDBP duplications rather than copy number variants as by qPCR
method [36].
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PvDBP duplications detected with specific PCR primers correlated strongly with qPCR esti-
mation of copy number. Samples that showed no amplifications by primers BF/AR (Malagasy-
type) [23] or BF/AR2 (Cambodian-type) [24] were all estimated to contain a single copy of
PvDBP by qPCR. A previous small scale test of only 25 Ethiopian P. vivax samples suggested
that multi-copy PvDBP infections are more common in Ethiopia than in other parts of the
Fig 4. Comparison of PvDBP copy number among symptomatic samples with different Duffy genotypes. These included Duffy-null homozygotes (FyBES/BES),
Duffy-null heterozygotes (FyA/BES or FyB/BES), Duffy-positive homozygotes (FyA/A or FyB/B), and Duffy-positive heterozygotes (FyA/B or FyB/X2). The geometric
median and stand deviation of the data were shown for each of the genotypes.
https://doi.org/10.1371/journal.pntd.0007222.g004
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world [24, 26]; increasing to 178 samples in this study confirms this finding. Genotyping 178
samples in total revealed that 65% of the Ethiopian isolates contained multiple PvDBP copies,
which is considerably more than any other P. vivax location, as indicated previously in a
worldwide study that included only very few samples from Ethiopia [24, 26]—this study pro-
vides more statistical robustness to that finding. It is formally possible that qPCR estimates of
copy number could be complicated by the presence of mixed infections, where qPCR would
generate an estimate that averages all clones present. However, in a previous study, P. vivax
infections in Ethiopia including Jimma were found to have a relatively low polyclonality rate
(4.3%) based on microsatellite typing [9]. The twenty samples in this study were confirmed as
monoclonal by microsatellites prior to whole genome sequencing. In P. vivax-endemic area
like Papua, Indonesia, asymptomatic samples have been showed with higher multiplicity of
infection and percentage of polyclonality than symptomatic samples based on microsatellite
Fig 5. Scatter plot based on principle component analyses showing variation in malaria symptoms among the P. vivax patients. PvDBP copy number of P. vivax
observed in each of the patient samples was indicated by different color circles. The first three axes represented 99.5% of the total variation from 12 malaria symptoms.
No clear cluster was observed among samples with single or multiple PvDBP copies, suggesting that malaria symptoms of these patients did not relate to PvDBP copy
number. Malaria symptom data are presented in S3 Table.
https://doi.org/10.1371/journal.pntd.0007222.g005
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markers [37]. Although P. vivax is not highly endemic in our study sites in Jimma, Ethiopia,
we cannot rule out the possibility that such differences may occur between our symptomatic
and asymptomatic samples and affect the comparison of PvDBP amplifications.
Cambodian-type duplications were five-times more common than the Malagasy-type.
Although primers BF/AR2 were used to diagnose the presence of the Cambodian-type PvDBP
duplications, this primer pair can also produce a 1,584-bp amplicon should there be Malagasy-
type duplications [24]. Among the 14 samples that were diagnosed with the Malagasy-type
duplications based on BF/AR, only two were detected with a 1,584-bp amplicon by BF/AR2,
likely due to limited quality of DNA extracted from dried blood on filter papers. The prepon-
derance of the Cambodian-type duplications among our samples corroborated the finding by
Auburn et al. [26] that indicated a 63% prevalence of the Cambodian-type duplications among
24 P. vivax isolates in Ethiopia. This finding suggested that PvDBP duplications observed in
the Ethiopian isolates may have arisen independently through local selection and adaptation,
or derived from Southeast Asia after P. vivax was re-introduced back to Africa [38, 39]. It is
possible that P. vivax with expanded PvDBP acquired better fitness and spread through Africa
where the majority of populations are Duffy-negative [3]. Though less common, the presence
of the Malagasy-type duplications in Ethiopian P. vivax may reflect a contemporary gene
exchange between populations via human movement.
More than four copies were detected in some of the Ethiopian isolates, higher than that
reported in Madagascar (up to two copies) [23] and Southeast Asia (two and three copies) [24,
25]. Our findings were consistent with earlier studies that reported high-order PvDBP copies
among a smaller number of P. vivax samples in Ethiopia [22, 26]. Gene duplication can gener-
ate new gene functions or alter gene expression patterns [40]. For examples, in P. knowlesi
duplication of PkDBP-alpha and deletion of PkDBP-gamma allow the parasite to invade
human erythrocytes that lack surface Neu5Gc, a form of sialic acid P. knowlesi requires for
binding [41]. In P. falciparum, duplications of the Pfmdr1 gene resulted in increased resistance
to antimalarial drug mefloquine [42–45]. While we did not detect any formal association
between PvDBP copy number and Duffy negativity, it is worth noting that in other parts of the
world such as Cambodia, India, and Brazil where only a small proportion of Duffy-negative
individuals live, PvDBP expansion was observed with much lower frequency [24], with the
exception of such in Thailand where a moderate rate (30%) of PvDBP duplications was
observed [26]. Apart from PvDBP, another gene PvEBP, which harbors all the hallmarks of a
Plasmodium red blood cell invasion protein, including conserved Duffy-binding like and C-
terminal cysteine-rich domains [46], has been recently shown to be variable in copy number
among the Malagasy P. vivax [47]. Functional analyses indicated that region II of this gene
bound to both Duffy-positive and Duffy-negative reticulocytes, although at a lower frequency
compared to PvDBP, suggestive of its role in erythrocyte invasion [48]. While we detected only
a single copy of PvEBP in the 20 Ethiopian P. vivax samples based on whole genome sequences,
further investigation is needed on a larger sample. The functional significance of PvDBP
expansion merits further investigations through comparison of gene expression patterns and
in-vitro binding assay of varying PvDBP dosage, and study of P. vivax isolates from Duffy neg-
ative individuals is clearly a high priority.
While we observed no association with Duffy negativity, with the clear caveat that Duffy
negative sample numbers were limited, we did observe a statistically significant higher number
of P. vivax isolates with multiple PvDBP copies in FyA/FyBES compared to FyB/FyBES and
FyB/FyB, as well as FyA/B compared to FyB/FyBES and FyB/B. Given that PvDBP has a higher
binding affinity with erythrocytes expressing the FyB than the FyA antigens [49], it is possible
that P. vivax expanded the PvDBP gene into multiple copies in order to increase binding affin-
ity to erythrocytes that express FyA antigen. The observation of a low number of P. vivax
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infections in the FyA/A patients in this study lends support to the association between FyA
antigen and a reduced risk of clinical vivax malaria in humans [49, 50]. While Duffy-negative
heterozygotes in Papua New Guinea and the Brazilian Amazon region were previously shown
with reduced erythrocyte susceptibility to P. vivax infection [51, 52] and a higher level of anti-
PvDBP antibodies compared to Duffy-positives [53], the relative high proportion of Duffy-null
heterozygotes (FyA/FyBES and FyB/FyBES) among our P. vivax-infected patients suggested
that some lineages of P. vivax (such as those in Ethiopia) may have evolved with higher binding
or invasion efficiency to erythrocytes with reduced Duffy antigen expression, perhaps through
PvDBP expansion. In addition, we also observed a statistically significant higher number of P.
vivax isolates with multiple PvDBP copies in symptomatic infections compared to asymptom-
atic infections. It is therefore possible that increased expression of PvDBP as a result of gene
expansion may play a role in evading the immune response developed by the infected individ-
uals, leading to symptoms. Further study with higher numbers of asymptomatic samples is
needed to draw a definite conclusion. Moreover, symptoms and parasitemia of the samples
were measured only at the initial stage of the infection rather than at various follow-up time
intervals. Thus, it is yet unclear if high PvDBP copies of the parasites will increase the duration
and/or severity of symptoms in the infected individuals over time. Given that age, gender and
ethnicity did not correlate with PvDBP copy number, parasites with single or higher PvDBP
copies could all cause infection equally within the host population.
To conclude, an exceptionally high prevalence of PvDBP expansion was observed among
Ethiopian P. vivax isolates, of which the majority were Cambodian-type duplications, and
higher order PvDBP copy number variants were identified by both qPCR and whole genome
sequencing. Duffy-negative heterozygotes did not show a significantly higher PvDBP copy
number than the Duffy-positives, but symptomatic infections had a significantly higher copy
number than the asymptomatic ones. For the symptomatic samples, PvDBP copy number was
not significantly associated with parasite density, age, gender and ethnicity. The functional sig-
nificance of common PvDBP expansion and the presence of high copy number variants
among the Ethiopian P. vivax are unclear. Our ongoing investigations focus on PvDBP copy
number variation in expanded Duffy-negative homozygote individuals. PvDBP copy number
in homozygous Duffy-negative infections and its correlation with symptoms are yet to be
explored.
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